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SUlTIITIary 
Mice deficient in the src-related protein tyrosine kinase, Lyn, exhibit splenomegaly and accu- 
mulate lymphoblast-like and plasma cells in spleen as they age, resulting in elevated levels of 
serum IgM  (10-20-fold of control) and glomerulonephritis due to the presence of immune 
complexes containing auto-reactive antibodies.  It remains unclear,  however, how antibody- 
producing cells are accumulated in the lymphoid tissues of Lyn -/- mice.To elucidate the role of 
Lyn in B  cell function, we have studied the proliferative responses to various stimuli and Fas- 
mediated apoptosis in B cells from young Lyn -/- mice which do not yet show apparent abnor- 
mality such as splenomegaly. Compared with control B cells, Lyn -/- B cells were hyper respon- 
sive to anti-lgM-induced proliferation and defective in FcyRIIB-mediated suppression orB cell 
antigen receptor (BCR) signaling,  indicating that Lyn is involved in the negative regulation of 
BCR signaling.  In addition, the BCR-mediated signal in Lyn -/- B ceils, unlike that in control 
B cells, failed to act in synergy with either CD40- or IL-4 receptor-triggered signal in inducing 
a strong proliferative response, suggesting that the BCR signaling pathway in Lyn -/- B cells is 
altered from that in control B cells. Furthermore, Lyn -/- B cells were found to be impaired in 
the induction of Fas expression after CD40 ligation and exhibited a reduced susceptibility to 
Fas-mediated apoptosis. Moreover, BCR cross-linking in Lyn -/- B ceils suppressed Fas expres- 
sion induced by costimulation with CD40 ligand and IL-4. Collectively, these results  suggest 
that the accumulation of lymphoblast-like and plasma  cells in Lyn -/-  mice may be caused, in 
part, by the accelerated activation of B cells in the absence of Lyn, as well as the impaired Fas- 
mediated apoptosis after the activation. 
T 
he B  cell antigen receptor (BCR) 1 consists  of mem- 
brane immunoglobulin M  (IgM) non-covalently asso- 
ciated with  disulfideqinked heterodimers of Igor and  Ig[~ 
subunits which couple mlg to several  protein tyrosine ki- 
nases  (PTKs)  (1). Cross-linking of the  BCR  rapidly acti- 
vates  two classes of PTKs: the src family kinases  (Lyn, Fyn, 
Blk, Hck, and Lck) (2-5)  and the Syk kinase  (6, 7), result- 
ing in the phosphorylation of several proteins (8, 9), includ- 
ing PTKs themselves, Igor and Ig[3 (10), phospholipase C-y 
(11),  phosphatidylinositol  (PI)-3  kinase  (12,  13),  the  pro- 
tooncogene  product Vav  (14-16),  Ras  GTPase-activating 
protein (17), Shc (18), and HS1 (19). 
The src-related kinase, Lyn, is expressed preferentially in 
hematopoietic cells  and in cells  of neural tissues  (20,  21). 
Lyn is physically associated with the BCR in B cells and is 
rapidly phosphorylated upon receptor cross-linking  (2-5). 
1Abbreviations used in this paper: BCR, B cell antigen receptor; CD40L, 
CD40 ligand; Fc"/IIRB,  B cell receptor for IgG Fc region; lgM, mem- 
brane immunoglobulin M; NMS, normal mouse serum; Pl, propidium 
iodide; PTK, protein tyrosine kinase; SHP-1, hematopoitic cell phos- 
phatase; smlg, cell surface IgM. 
Lyn interacts with and phosphorylates the Syk kinase  (22, 
23),  the  HS1  protein  (19)  and  the  Cbl  protooncogene 
product (24), and associates with the p85 subunit of the PI-3 
kinase after BCR cross-linking (12,  13).  BCR also associ- 
ates  with  a  number  of cell  surface  molecules,  including 
CD45,  a phosphotyrosine phosphatase  that is  essential  for 
anti-IgM-induced  proliferation  of B  ceils  (25,  26),  and 
CD19, a member of lg gene superfamily whose cross-link- 
ing  inhibits  B  cell  proliferation via  anti-IgM  stimulation 
(27, 28). Interestingly, Lyn has been shown to interact with 
both CD45  and CD19  (29,  30).  These observations indi- 
cate  that  Lyn participates  in BCR-mediated  signal  trans- 
duction through multiple pathways. The functional signifi- 
cance of Lyn in the BCR signaling was first  demonstrated 
in cell lines.  A  Lyn-deficient mutant of the chicken B  cell 
line DT40, generated through homologous recombination, 
exhibited delayed Ca  2+ influx but enhanced inositol 1,4,5- 
triphosphate  (IP3) accumulation, indicating that Lyn regu- 
lates  Ca  2+  mobilization through a process independent of 
IP  3 generation  (31). Moreover, using antisense oligonucle- 
otides, Lyn was  shown to be required for anti-lgM-medi- 
ated  cell  cycle arrest  in  both  murine  BCL1  and  human 
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Lyn in the negative regulation of BCR signaling. 
In addition to a role of Lyn in regulating BCR signaling, 
biochemical  analysis  has  suggested  its  involvement  in  the 
signaling  pathway  through  CD40  (33,  34),  a  member  of 
the TNF receptor family that plays a critical role in the sur- 
vival,  growth,  differentiation  and  apoptosis  of B  lympho- 
cytes (35-37). Lyn thus appears to be involved in the signal 
transduction from multiple receptors on B cells. 
Lyn -/-  mice, generated  recently  by gene  targeting,  ex- 
hibited  splenomegaly with  age  and  accumulated  the  lym- 
phoblast-like  and plasma cells  in spleen  (38, 39). There was 
a high concentration  of serum  IgM in Lyn  /-  mice, and a 
significant  number  of Lyn  -/-  mice  showed  glomerulone- 
phritis due to the presence of immune complex containing 
auto-reactive  antibodies.  It remains  unclear, however, how 
large  numbers  of antibody producing  cells  accumulate  in 
lymphoid tissues of Lyn -/- mice. Recent studies  revealed a 
critical  role for the  CD40-mediated  signal in upregulating 
Fas  expression  and inducing susceptibility to Fas-mediated 
apoptosis in B  cells  (40-42). By contrast, BCR  engagement 
was shown to protect B  cells from Fas-mediated  apoptosis 
(43), indicating that Fas susceptibility is positively and neg- 
atively regulated by CD40- and BCR-mediated signals, re- 
spectively. It has been suggested that activated bystander B 
ceils,  which  may produce  various Abs including  autoanti- 
bodies,  are  eliminated  by  Fas-dependent  apoptosis  (43). 
Since  Lyn was implicated  in  the  signal  transduction  path- 
ways  of both  CD40  and  BCR,  we  examined  whether 
Llm -/-  B  cells  have  defects  in  Fas-mediated  apoptosis. We 
demonstrate in the present study that Lyn-/- B cells are im- 
paired  in  Pas-mediated  apoptosis due  to both an impaired 
induction  of Fas expression and a reduced susceptibility to 
Fas-mediated  apoptosis.  In  addition,  B  cells  from  young 
Lyn -/  mice are hyper responsive to anti-IgM-induced pro- 
liferation  and defective in Fc'yRII-mediated suppression of 
signals  generated  by BCR  engagement. These  results  sug- 
gest that Lyn -/-  B  cells  have a reduced threshold  for anti- 
gen-triggered  activation,  and  may  survive  for  prolonged 
period  after  the  activation  due  to  impaired  Fas-mediated 
apoptosis, resulting in the accumulation of antibody-secret- 
ing cells. 
Materials  and Methods 
Reagents.  Goat F(ab')  2 and  intact  anti-mouse  IgM Abs pur- 
chased  from Southern Biotechnology Associates, Inc.  (SBA, Bir- 
mingham, AL)  were  extensively  dialyzed  in  PBS. The Jo2 anti- 
mouse  Fas Ab  and  anti-mouse  CD8 Ab  were  purchased  from 
PharMingen  (San Diego, CA). The  IC10 rat  anti-mouse  CD40 
Ab and the biotinylated Jo2 anti-mouse Fas Ab were kindly pro- 
vided by Dr. M. Howard (DNAX, Palo Alto, CA) and Dr. S. Na- 
gata  (Osaka  Bioscience  Institute),  respectively. Culture  superna- 
tants  from a myeloma cell line  producing soluble  CD40 ligand 
CD8 fusion protein (CD40L) (44), generously provided by Dr. P. 
Lane (Basel Institute  for Immunology), were used at a fourfold di- 
lution that was optimal for inducing proliferation  of  splenic B cells. 
Recombinant interleukin-4  was purchased  from R&D  Systems 
(Minneapolis,  MN). 
Cells and Cell Cuhure.  Cells were  cultured at  370(;  with  5% 
CO2 in a humidified atmosphere,  in RPMI 164(I containing 5 ￿ 
10 -5 M  2-mercaptoetbanol, 25  lxg/ml  of Gentamycm, supple- 
merited  with  10%  heat-inactivated  fetal  calf sermn  (GIBCO 
BRL, Gaithersburg,  MD). Splenic B cells were isolated from 4-8- 
wk-old mice after T cell depletion by treatment with anti  mouse 
Thyl.2 mAb for 30 min on ice and then with complement for 30 
min at 37~  followed by Ficoll-Hypaque density  centrifugation 
and incubation at 37~  for 1 h to remove adherent cells. Approx- 
imately 90-95% of the isolated cells were found to express  the 
B cell marker B220. 
Prol!feration Assay.  Splenic B cells (5 X  10S/ml, 100 Ixl) were 
placed  in 96-well flat-bottom plates and cultured in the presence 
of various  stimuli. The cultures  were pulsed  for the last 6 h with 
[3H]thymidine  (1  Ixci/ml)  and the mean [3H]thymidine  incorpo- 
ration  and standard  deviation  were  calculated  for triplicate  cul- 
tures. 
lmmunqfluorescence Analysis.  For C1)40 staining, cells (if)  a) were 
incubated in 50 Ixl of 10 lxg/ml of the I C10 antibody on ice for 
20 rain, followed  by a phycoerythrin (PE) conjugated goat anti- 
rat  Ig Ab (SBA). For Fas staining, cells were incubated with  nor- 
real mouse sermn (NMS)  to block Fc receptors  and then stained 
with the biotinylated Jo2 anti-mouse Fas Ab, followed by staining 
with streptavidm  conjugated PE (SAPE; SBA). Cells stained  with 
NMS and then SAPE served  as controls.  Cells were fixed in  1% 
paraformaldehyde before analyzing with a FACScan ~0 flow cyto- 
meter (Becton Dickinson & Co., MountamView, CA). 
Analysis for CellDeath.  Cells  were  stained  with  1 p,g/ml  of 
propidium  iodide  (Pl)  in  PBS  containing  2%  FCS  and  0.02% 
NaN3 for 5 rain on ice and the percentage of Pl positive  (dead) 
and negative  (live) cells were determined with a FACScan ~ flow 
cytometer. 
Results 
Prol!femtive Responses  to  Various Stimuli  in  Lyn -/-  B  Cells. 
In the previous study, we have demonstrated that lympbo- 
blast-like cells  carrying Mac-1  antigen and cytoplasmic IgM 
accumulated in spleen of Lyn -/- mice (39).To find out the 
intrinsic  defects of Lyn-/-  B  cells, we have investigated the 
function of B cells from young (4-8-wk-old) mice which do 
not  yet  show  apparent  abnormality  such  as  splenomegaly 
and  the  accumulation  of lymphoblast-like  cells.  In  accor- 
dance with earlier observations (39), the proliferative responses 
of Lyn -/-  B  cells  to  either  soluble  CD40 ligand-CD8  fu- 
sion  protein  (CD40L  or L), or  CD40L plus  an  anti-CD8 
Ab  (L  +  anti-CDS), were  considerably reduced  compared 
with  control  B  cells  (Fig.  1 A). The  reduced  response  to 
CD40 ligation is unlikely to reflect a low level of CD40 ex- 
pression as the level of CD40 on Lyn -/- B cells was found to 
be similar as that on control B cells (Fig. 2 A).The data dem- 
onstrate that Lyn, which was reportedly activated by CD40 
ligation (33, 34), is indeed critical for CD40-mediated  pro- 
liferative response in B  cells. Since Lyn -/- B cells  could still 
respond  to  CD40 ligation  to  some  extent, it is  likely  that 
other PTKs, such as Fyn and Syk which were also activated 
by CD40 ligation (33, 34), may be involved in the observed 
proliferative  response.  These  PTKs,  however,  could  not 
compensate for the activity of Lyn to restore a normal pro- 
liferative response induced by CD40 ligation. 
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Figure 1.  Proliferative  responses of control and Lyn  /  B cells to vari- 
ous stimuli. (A) Splenic B cells were stimulated with goat F(ab')  2 anti-IgM 
Abs (5 I.tg/rrd), IL-4 (200 U/ml), CD40 ligand (L), CD40 ligand plus an 
anti-CD8 Ab (5  btg/ml) or various combinations of these stimuli. (B) 
Splenic B cells were cultured with indicated amounts of goat F(ab')  2 or 
whole anti-lgM Abs. In both A and B, representative results of five inde- 
pendent experiments are shown. 
Much to our surprise,  Lyn -/- B  cells  from young mice 
were  hyper  responsive  to  anti-IgM-induced  proliferation 
compared  with  control B  cells. As  indicated  in  the  dose- 
response  profiles  (Fig.  1  /3), Lyn -/-  B  cells  responded 
greatly to  even  a  low dose  of F(ab') 2 anti-IgM  (1  I.Lg/ml) 
within  1  d  of culture  whereas  control  B  cells  responded 
poorly even after 2  d. At a higher dose of F(ab') 2 anti-IgM 
(20  btg/ml), however, the proliferative response was similar 
in  Lyn -/-  and  control B  cells  (Fig.  1 B, compare  [3H]thy- 
midine  incorporation  of Lyn -/- vs. control B  cells  stimu- 
lated  with  20  btg/ml  of F(ab')  2 anti-IgM  for 2  d). This  is 
likely because  the  response  of Lyn -/- B  cells  reached near 
plateau  at  relatively  high  concentrations  of anti-IgM Abs 
whereas the response of Lyn  +/+ B ceils continued to increase. 
The hyper responsiveness of Lyn -/- B cells  to antigen stim- 
ulation does not reflect an increased expression of cell sur- 
face  IgM  (slgM)  as  the  level  of slgM  is similar  in  control 
and  Lyn -/-  B  cells  (Fig.  2  C). These  results  demonstrate 
that  Lyn -/- B  cells  have a  reduced  threshold  for anti-IgM 
induced proliferation with an accelerated time course than 
do control B cells. 
Another interesting finding is that in Lyn -/- B  cells,  the 
whole  anti-IgM Abs induced  a  similar, if slightly  reduced, 
proliferative response as did F(ab')  2 anti-IgM Abs (Fig. 1 B), 
whereas  in control B  cells,  the proliferative  responses were 
significantly reduced when stimulated with whole anti-IgM 
Abs  which  have  been  shown  to  cross-link  BCR  with 
FcyP,  IIB, a  predominant  form of Fcy receptors  expressed 
on B  cells  (45-47). The results demonstrate  that FcyRIIB- 
mediated downregulation of BCP, signaling is not properly 
functional  in  the  absence  of Lyn, although  it  has  not yet 
been  studied  whether  Lyn  is  activated  by  cross-linking 
FcyRIIB. 
Response to IL-4 does not seem to be impaired in Lyn -/- 
B  cells as indicated by both the proliferation  (Fig. 1 A) and 
upregnlation of CD40 expression in response to IL-4 (Fig. 
2  B). Notably, stimulation with  CD40L in the presence  of 
IL-4 (L +  IL-4) for one or 2 d induced a normal or some- 
what higher proliferative response in Lyn -/- B  cells relative 
to control B  cells,  suggesting a possibility that  IL-4 recep- 
tor-mediated signals acted in synergy with and restored the 
CD40-mediated  proliferative  signal  which  was  otherwise 
reduced  in  Lyn -/-  B  ceils  (Fig.  1  A).  Stimulation  with 
CD40L plus both IL-4 and anti-IgM also induced a normal 
proliferative response in Lyn -/- B cells on day 1, but unlike 
the combination of CD40L plus IL-4, the response was sig- 
nificantly reduced in Lyn -/- B  cells, as compared with con- 
trol B  cells, on day 2. It appears that the restored prolifera- 
tive response of Lyn -/- B cells induced by CD40L plus IL-4, 
when combined with the hyper responsiveness to anti-lgM 
stimulation, was accelerated and decayed more rapidly than 
that  of control  B  cells.  Alternatively,  the  BCR-mediated 
abnormal signal in Lyn -/- B  ceils  may have suppressed the 
restored proliferative response induced via CD40L plus IE-4. 
The  data  shown in  Fig.  1 A  also suggested that,  in the 
absence  of Lyn, the  BCR-mediated  signal failed to act in 
synergy with  CD40-  or IL-4 receptor-mediated  signals in 
inducing strong proliferative  responses.  In control B  cells, 
the combinations ofanti-IgM and CD40L or anti-IgM and 
IL-4 induced a strong proliferative response that was more 
than  the  sum  of that  induced  by  each  stimulation  alone 
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whereas  in  Lyn  /-  B  cells,  these  combinations  only acted 
additively, suggesting that  the BCR-mediated  signal trans- 
duction  pathway  in  the  absence  of Lyn  is  clearly  distin- 
guished from that in control B  cells. 
Reduced  Fas  Induction  After  Various  Stimuli  in  Lyn -/-  B 
Cells.  We and others have recently found that CD40 liga- 
tion upregulated Fas expression and enhanced susceptibility 
to Fas-mediated apoptosis in B  cells  (40-43).  Since Lyn -/ 
B  cells  exhibited  a reduced proliferative response to CD40 
ligation, Fas expression  (Fig. 3) and Fas-mediated apoptosis 
(Fig. 4) after various stimuli were investigated. In both con- 
trol and Lyn-/- mice, fresh splenic B cells (Fig. 3 A) or B cells 
stimulated with anti-IgM, IL-4 or anti-IgM plus IL-4 (data 
not shown), expressed only a low level of Fas antigen, con- 
firming our earlier finding that Fas is not induced by BCR- 
cross-linking  or  IL-4  stinmlation  (42).  Stimulation  with 
CD40L upregulated Fas expression in control but not Lyn-/- 
B  cells  (Fig.  3  B).  CD40L  plus  an  anti-CD8  Ab  which 
delivered a stronger signal as judged by the proliferative re- 
sponse (Fig. 1 A), however, induced Fas expression in Lyn  / 
B cells to a similar level of that in control B  cells  (Fig. 3  C), 
suggesting that  Fas  induction  in  Lyn -/-  B  cells  required  a 
stronger  CD40-mediated  signal.  CD40-mediated  Fas  in- 
duction could be restored by IL-4 (Fig. 3 E), in accordance 
with  the  observation  that  CD40L  plus  IL-4  restored  the 
proliferative response  (Fig. 1 A). The reduced Fas induction 
by CD40L in Lyn -/  B  cells  could not be restored by co- 
stimulation  with  anti-IgM  (Fig. 3  D), in keeping with  the 
observation that anti-IgM and  CD40L did not act in syn- 
ergy to restore a normal proliferative response in Lyn -/- B 
cells.  Moreover,  anti-IgM  stimulation  downregulated  Fas 
expression  of Lyn -/- B  cells  induced by CD40L plus  IL-4 
(compare  Fig.  3,  E  and  F).  Interestingly,  while  a  normal 
proliferative response was induced on day  1 by stimulation 
with either CD40L plus IL-4 or CD40L plus IL-4 and anti- 
IgM (Fig. 1 A, day 1), Fas expression was induced on day 1 by 
treatment with CD40L plus IL-4 but not CD40L plus IL-4 
in the presence of anti-IgM (data not shown). Collectively, 
these  results  revealed  two  abnormal  aspects  of Lyn  /  B 
cells  in the induction of Fas expression: one is that  Fas in- 
duction in Lyn -/- B  cells required a stronger CD40-medi- 
ated signal, and  the  other is  that the  abnormal BCR-trig- 
gered signal suppressed Fas induction. 
Impaired Fas-mediated Apoptosis  in Lyn-/- B  Cells.  Having 
shown the abnormality of Fas induction in Lyn -/-  B  cells, 
we next examined the susceptibility to Fas-mediated apop- 
tosis in these B  cells. In accordance with our prior finding, 
both control and Lyn -/- B cells  activated for 1 d were resis- 
tant to Fas-triggered apoptosis (data not shown). B  cells  ac- 
tivated for 2 d were therefore examined for Fas susceptibil- 
ity.  Consistent  with  the  reduced  Fas  expression,  Lyn -/-  B 
cells  stimulated by CD40L alone, CD40L plus anti-IgM or 
CD40L plus anti-IgM and IL-4, all  exhibited reduced sus- 
ceptibility  to  Fas-mediated  apoptosis  after  treatment  with 
the Jo2 anti-Fas Ab for 4 h  (Fig. 4 A) or 16 h  (Fig. 4/3). In 
keeping  with  the  observation  that  IL-4  acted  in  synergy 
with CD40-mediated  signals to restore  a normal prolifera- 
tive response  (Fig. 1 A) and upregulate  Fas expression  (Fig. 
3 E), Lyn -/- B  cells  stimulated with CD40L plus IL-4 un- 
derwent Fas-triggered apoptosis in a similar dose dependent 
manner as did control B  cells after treatment with increasing 
concentrations of the Jo2 anti-Fas Ab (Fig. 4 A), or after in- 
cubation with the anti-Fas Ab for 16 h  (Fig. 4 B). 
Although a similar level of Fas  expression  was observed 
in control and Lyn -/- B  cells  stimulated with CD40L plus 
the  anti-CD8 Ab, Lyn -/  B  cells  exhibited  a  reduced  sus- 
ceptibility  to the  anti-Fas Ab-induced apoptosis relative  to 
control  B  cells  (Fig.  4). The  data  suggest  that  a  stronger 
CD40-mediated  signal  (CD40L  plus  anti-CD8)  upregu- 
lated Fas expression but did not completely restore the sus- 
ceptibility  to  Fas-mediated  apoptosis  in  Ly,  /  B  cells. 
CD40 ligation has recently been shown to not only induce 
cell surface Fas expression, but also enhance Fas susceptibil- 
ity in B  cells  (40-42). It is thus likely that Fas susceptibility 
was more affected by the Lyn-dependent, CD40-mediated 
signal, whereas  Fas induction could be restored by a stron- 
ger  CD40 ligation  in  the  absence  of Lyn. Taken  together, 
these results demonstrate that L),n-/- B cells are itnpaired in 
the induction  of both Fas  expression and  Fas  susceptibility 
induced by CD40L. Furthermore, the BCR-mediated  sig- 
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Figure 4.  Fas-mediated  apoptosis of activated B cells. Splenic B cells stimulated for 2 d as in Fig. 3 were 
treated with indicated amounts of the Jo2 anti-Fas Ab for 4 h (A) or treated with 1 Ixg/ml of the anti-Fas 
Ab for 16 h (B). Percent cell death was calculated by the formula:  % experimental cell death -  % spontane- 
ous cell death/100 -  spontaneous cell death. Shown in A is one of two experiments which gave similar re- 
sults. Shown in B are the average and standard deviation of five independent experiments. Unpaired stu- 
dent's t test was calculated in B and the P values indicated by * were <0.05. 
nal in the  absence of Lyn interfered with the induction of 
Fas expression. 
Discussion 
To begin to elucidate the role of Lyn in B cell function, 
we have investigated in the present study the function orB 
cells from young Lyn -/- mice. We reasoned that while  the 
aged  Lyn -/-  mice,  which  have  accumulated  abnormal  B 
cells, are suitable for studying the consequence of B cell de- 
fects, young mice are better models to investigate the cause 
of the B  cell abnormality. The results presented here dem- 
onstrate that Lyn -/- B  cells are hyper responsive to antigen 
stimulation  and  have  defects  in  Fas-mediated  apoptosis, 
suggesting that  Lyn -/- B  cells are likely to be activated by 
low doses of antigen stimulation and may not be efficiently 
eliminated  after  the  activation  due  to  impaired  Fas-medi- 
ated  apoptosis, which  has  been implicated  in the  eliimna- 
tion of activated bystander B  cells  (43). 
In contrast to the finding here that Lyn-/- B  cells are hy- 
per  responsive  to  BCR-cross-linking,  earlier  studies  have 
suggested a severe reduction in anti-IgM-induced prolifera- 
tion in Lyn -/- B  cells  (38, 39). Several possibilities could be 
considered  for  the  observed  discrepancy. IgM  +  B  cells  in 
young  mice  may  be  characteristically  distinguished  from 
those  in  aged  mice,  for  example  BCP,-associated  signal 
transduction  molecules including the src family protein ty- 
rosine  kinases  or  phosphatases  may  be  differentially  ex- 
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pressed. It is also possible that the reduced proliferative re- 
sponse  of Lyn -/-  B  ceils  observed  in  earlier  studies  may 
reflect a decreased percentage of antigen-responsive B  cells 
due  to the  accumulation of abnormal B  cells  which  carry 
Mac-1  antigen and cytoplasmic IgM and  therefore  do not 
respond to BCR  cross-linking (39). The hyper responsive- 
ness to anti-Ig-induced proliferation  observed in Lyn -/- B 
cells is in accordance with the previous findings that Lyn -/- 
DT40  cells  exhibited  enhanced  IP-3  generation  (31)  and 
that Lyn is involved in the cell cycle arrest induced by anti- 
IgM stimulation in B lymphoma cell lines (32). It is notable 
that B  cells  from young Lyn -/- and control mice are phe- 
notypically similar and express a similar level of surface IgM 
(Fig.  2  B).  The  hyper  responsiveness  observed  in  young 
Lyn -/-  B  cells  thus  indicates  an  intrinsic  defect  in  B  cell 
function, but not a  consequence  of abnormalities  in other 
cell types. 
The  whole  anti-IgM  Ab  is  known  to  cross-link  the 
BCP,  with  FcyP,  IIB, a  predominant  form  of the  Fcy  re- 
ceptors expressed on B  cells, resulting in the suppression  of 
BCt<-mediated  signaling  (45-47). As  shown  in  Fig.  1  B, 
Lyn -/- B  cells apparently have defects in FcTRII-mediated 
suppression. It is intriguing to note that recently generated 
FcTR.II  -/-  mice have  been  shown  to  have  enhanced  im- 
mune responses to both T-dependent and -independent an- 
tigens  (48), a  phenomenon  also  observed  in  Lyn -/-  mice 
(39).These results suggest a critical role for Lyn in Fc'yP,.II- 
mediated  downregulation  of BCR.-mediated  proliferative response  although  it  remains  to  be  examined  how  Lyn  is 
involved in Fc',/P,-mediated suppression of BCR  signaling. 
The hyper responsiveness to anti-IgM-induced prolifera- 
tion  and  lack  of FcyRIIB-mediated  suppression  of BCR 
signaling  observed  in  Lyn -/-  mice  are  similar  to  that  ob- 
served  in  B  cells  from moth-eaten  (me)  and  viable moth- 
eaten  (me  v)  mice  (49, 50), which  express  no  or aberrantly 
spliced nmtant SHP-1  protein  (also called PTPIC  or HCP), 
respectively (51-53). In addition, both  me and Lyn  /- mice 
accumulate  plasma  ceils  in  their  lymphoid  tissues  (38, 39, 
54,  55).  Both  SHP-1  and  Lyn  thus  negatively  regulate 
BCR.  signaling for proliferation. It is  conceivable  that Lyn 
may directly or indirectly interact with SHP-1  in BCR  sig- 
naling,  a  hypothesis  that  can  be  proved  by  detailed  bio- 
chemical  analysis. Unlike  me mice  which  die  shortly  after 
birth and predominantly  contain B-1  (CD5 +) type periph- 
eral B  ceils  (55, 56), Lyn -/- mice are viable for at least one 
year and  contain  a  largely  conventional  B  cell  population 
with increased number of abnormal CD5-, B220-, Mac-i- 
and cytoplasmic ~+ lymphoblast-like cells as they age (39). 
The less severe phenotype  in Lyn -/-  mice  compared with 
me mice  may  suggest  that  Lyn  and  SHP-1  may  regulate 
overlapping, but distinct B  cell signaling pathways. It is also 
conceivable  that SHP-1, which  is expressed in  various  tis- 
sues and  cell types, may regulate  additional  signaling path- 
ways (55). 
Stimulation with CD40L induced  Fas expression in con- 
trol  but  not  Lyn -/-  B  cells, demonstrating  that  Lyn is  in- 
volved in the  CD40-mediated  induction  of Fas. A  stronger 
CD40  ligation, generated  by cross-linking CD40L with  an 
anti-CD8 Ab, almost completely restored Fas induction  but 
only  partially  restored  the  susceptibility  to  Fas-mediated 
apoptosis. The data suggest that Lyn is also involved in  the 
enhancement  of  Fas  susceptibility.  IL-4-mediated  signal 
could  compensate  for  the  impaired  CD40  signaling  in 
Lyn-/- B  cells as CD40L plus IL-4 restored the proliferative 
response, the induction  of Fas expression and the  suscepti- 
bility  to  Fas-mediated  apoptosis.  B  cells  are  activated  by 
stimulation  through  multiple receptors  (37). Signals through 
BCR,  IL-4R and  CD40  apparently act in synergy in nor- 
mal B  cells  to  generate  strong proliferative responses  since 
the combination of any two of the above three signals gen- 
erated a much stronger growth signal that is more than the 
sum of that induced by each stimulation alone (Fig. 1 A). In 
the  absence  of Lyn, the  enhanced  BCR-mediated  growth 
signal  failed  to  cooperate  with  either  CD40-  or  IL-4R.- 
mediated signals to provide a strong synergy in inducing B 
cell growth. Although  further studies are required  to clarify 
at  the  molecular  level  how  the  abnormal  signals  through 
BCR  and CD40 result in the dysfunction of B cells, the re- 
suits presented here provided evidence of a critical role for 
Lyn in regulating  not  only the  signal transduction  through 
BCR  and  CD40  but  also  the  interactions  between  these 
signals and with other signals. 
Engagement  of BCP,  has  been  shown  to  rescue  Fas- 
mediated apoptosis in B  cells (43).  The mechanism for this 
protection  is  unclear,  but  our  preliminary  data  suggest  a 
possible role ofbcl-XL in regulating the Fas susceptibility of 
B  cells.  It is  thus  intriguing  to  examine  whether  the  en- 
hanced BCR  signaling in  Lyn -/-  B  cells would  result in  a 
rapid  and  sustained  induction  of the  anti-apoptotic  gene 
such as bcl-x  L. As is the case for B  cells in me or me  v nfice, 
the  enhanced  BCR-mediated  signal  in  Lyn -/-  B  cells  is 
likely to lead to accelerated activation and differentiation  of 
B cells in response to even low doses of antigen stimulation. 
The impaired Fas induction  and Fas-mediated apoptosis af- 
ter B  cell activation in Lyn-/- B  cells, along with the obser- 
vation that the abnormal BCR  signaling suppressed Fas ex- 
pression, indicate  that activated Lyn -/-  B  cells may not be 
efficiently eliminated by Fas-mediated apoptosis.The  accu- 
mulation  of lymphoblast-like  and  plasma  cells  in  Ll,n  l- 
mice  may  be  consequent  to  the  combined  effects  of an 
accelerated  activation/differentiation  of B  cells and  an im- 
paired Fas-dependent elimination  of activated B  cells. 
Although  apoptosis of B  cells may be mediated  through 
multiple  pathways,  Fas-mediated  apoptosis plays an  essen- 
tial  role in  maintaining  peripheral  B  and  T  cell  tolerance. 
Mutations  in  gene  Fas  or its ligand  result  in  autoimmune 
disorders of Ipr and gld mice, respectively (57). While  Fas is 
important  for both  T  and  B  cell  function,  Lyn is not  ex- 
pressed in  T  cells  and  correspondingly  no  obvious  defects 
have been observed in Lgn-/- T  cells (38, 39). Lyn-/- mice 
thus provide a unique model of autoimmune  disorders that 
are  largely  due  to  the  impaired  function  of B  cells.  It  re- 
mains to be investigated whether there is a human counter- 
part of a similar autoimmune disorder arising from the dys- 
function of Lyn or other src family tyrosine kinases. 
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